NGL Fine Chem LtdQ3 FY21Pharmaceuticals & Biotechnology

NGL Fine Chem Ltd

Q3 FY21 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Revenue guidance

Category 2

→The company anticipates consistent growth over the next 3-5 years by adding new products from their existing pipeline.
→Plans to commercialize 3 new products this year and 3-4 products next calendar year, aiming for a product basket of 27-30 within two years.
→Targets to reach a quarterly revenue run rate of Rs. 100-110 crores within the next two to two-and-a-half years, driven by increased outsourcing, Macrotech expansion, and process debottlenecking.
→Greenfield expansion at Tarapur (50% capacity addition) expected to commercialize by mid-FY24, funded by Rs. 100 crores CAPEX.
→Market opportunities for top 10 products estimated at Rs. 400-500 crores annually.
→Focus remains on niche molecules with sufficient pipeline to keep growth intact.
→Confident of maintaining and growing market share in key products and geographies including Latin America, Africa, and the US.

Category 3

→The company expects to reach a quarterly revenue run rate of around ₹100-110 crores within the next two years, driven by Macrotech expansion, increased outsourcing, and debottlenecking efforts.
→EBITDA margins currently at about 23%, with potential downside of up to 5% if raw material prices remain high; margins expected to recover quickly if prices stabilize.
→Long-term margin range anticipated between 18-25%, influenced more by macroeconomic factors than internal changes.
→Net profit for Q2 FY22 was ₹14 crores with an 18% margin; future margins may stay under pressure for the next four quarters due to high costs.
→The company plans a ₹100 crore Greenfield expansion at Tarapur, expected to add 50% capacity by mid-FY24, supporting further growth.
→Overall, with strong demand and capacity expansions, sustained profit growth and stable margins are expected over the medium term.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for NGL Fine Chem Ltd and 1,400+ other companies.

Yes

→The company plans a Greenfield expansion at Tarapur with an expected CAPEX of Rs. 100 crores.
→This CAPEX will be funded through a mix of debt and internal accruals.
→No specific mention of new equity fundraising or IPO plans related to this expansion.
→The company is currently net debt-free, indicating a strong balance sheet to support funding.
→The Board has decided to proceed with listing on the NSE, with the listing process expected to complete within 6-8 months, but this is not explicitly linked to fresh fundraising.

Yes

→The company does not explicitly mention a specific current order book value in the transcript.
→Rahul Nachane indicates strong and growing demand, with no risk of losing orders due to capacity constraints.
→They are increasing outsourcing and expanding capacity (Macrotech expansion and Greenfield project) to meet demand.
→Outsourcing optimization expected around May/June next year.
→Aim to reach approximately Rs. 100 crore quarterly run rate in 2 to 2.5 years, indicating a robust order pipeline.
→Confident about continuing sales growth and market share gains.
→They have sufficient capacity levers and do not anticipate supply issues impacting order fulfillment.

Yes

→Macrotech expansion: Rs. 28 crores already incurred; awaiting final approvals; expected commercialization in next few weeks; will increase intermediate manufacturing capacity and contribute to revenues from Q4 onwards.
→Greenfield expansion at Tarapur: Planned Capex of Rs. 100 crores, bringing 50% capacity addition; approvals and land are in place; construction to start soon (contractor selection in progress); expected to commercialize and start production by mid FY24.
→Expansion funded through mix of debt and internal accruals.
→Aim to increase outsourced production to 15%.
→Ongoing efforts in debottlenecking and process improvements to drive near-term growth.
→Construction costs initially higher due to metal and equipment price increases; expected to moderate as metal prices stabilize.

How does NGL Fine Chem Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1NGL Fine Chem Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like NGL Fine Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.